US2019100505A1PendingUtilityA1
Inhibitors of bruton's tyrosine kinase
Est. expiryDec 5, 2033(~7.4 yrs left)· nominal 20-yr term from priority
A61P 35/02A61P 37/06A61P 35/00A61P 37/02A61P 43/00A61P 37/00A61P 29/00A61P 17/02A61P 19/10A61P 19/08A61P 19/00A61P 19/02A61K 31/397A61K 31/497C07D 417/14C07D 401/14C07D 401/04C07D 403/12C07D 401/12C07D 413/14A61K 31/4025C07D 471/04C07D 409/14C07D 405/14A61K 31/53A61K 31/445
63
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Claims
exact text as granted — not AI-modified1 - 20 . (canceled)
21 . A compound, wherein the compound is (R)-3-(1-(4-tert-butylbenzoyl)piperidin-3-ylamino)-5-(4-(morpholine-4-carbonyl)phenylamino)-1,2,4-triazine-6-carboxamide.Join the waitlist — get patent alerts
Track US2019100505A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.